Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer

The aim of this study is to evaluate the efficacy of nab-paclitaxel (on days 1 and 8 of a 21-day cycle) compared to the standard regimen of docetaxel plus carboplatin, both combined with trastuzumab and pertuzumab, as neoadjuvant therapies for HER2-positive breast cancer.

Trial Details

NCT ID
NCT07057427
Phase
PHASE3
Sponsor
Henan Cancer Hospital
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • Nab paclitaxel
  • Docetaxel and Carboplatin
  • Trastuzumab + Pertuzumab
Locations (sample)
  • Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

  • Age: 18-70 years old.
  • Clinical Tumor Stage: T2-T4d, or T1c with axillary lymph node positivity.
  • Histologically confirmed HER2-positive invasive breast cancer:
  • Note: HER2 positivity is defined as at least one assessment (either initial testing or central review) by the participating center's pathology depa…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →